The meeting will start promptly at 10:00 and is expected to finish at approximately 12:00
Please note that this agenda is subject to change before the meeting.
The Committee for Medicinal Products for Human Use (at the European Medicines Agency) has not yet given its regulatory opinion for Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer and as a consequence this discussion will take place in a part 2 session (part 2 sessions are closed to public observers).
To print an agenda, please right click and select 'Print' from the menu.
The next meeting will take place on Thursday 14 February 2019 at 10:00, at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Please note all timings are approximate.